Filing Flows › BillionToOne (BLLN) › Q3 2026 › vs Q2 2026
BillionToOne (BLLN) Q3 2026 vs Q2 2026 (quarter over quarter)
BillionToOne's revenue rose $13.5M (+12%) from $109M in Q2 2026 to $123M in Q3 2026. The biggest changes: Prenatal +$10.0M (+11%); Oncology +$3.4M (+25%); Clinical trial support and other services +$101K (+7%). Gross margin 70.9% against 70.5% (+0.4 pts).
BillionToOne, Q3 2026: revenue $123M (+47% year over year), operating margin 9.0%, net earnings $17.4M, operating cash flow $12.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 70.9% | 70.5% | +0.4 pts |
| Operating margin | 9.0% | 5.0% | +3.9 pts |
| Net margin | 14.1% | 7.4% | +6.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Prenatal | $104M | $94.2M | $10.0M | +11% |
| Oncology | $17.1M | $13.7M | $3.4M | +25% |
| Clinical trial support and other services | $1.6M | $1.5M | $101K | +7% |
| Revenue | $123M | $109M | $13.5M | +12% |
| Gross profit | $87.1M | $77.1M | $10.0M | +13% |
| Cost of revenue | $35.8M | $32.3M | $3.5M | +11% |
| Other income, net | $6.4M | $2.0M | $4.4M | +216% |
| Operating profit | $11.0M | $5.5M | $5.5M | +100% |
| Operating expenses | $76.1M | $71.6M | $4.5M | +6% |
| Pre-tax earnings | $17.4M | $7.5M | $9.9M | +131% |
| Research & development | $20.2M | $17.3M | $2.9M | +17% |
| SG&A | $55.9M | $54.3M | $1.6M | +3% |
| Net earnings | $17.4M | $8.1M | $9.3M | +116% |
| Income tax | $1K | −$536K | $537K | — |
| Depreciation & amortization | $2.0M | $1.8M | $144K | +8% |
| Share-based compensation | $9.7M | $8.2M | $1.5M | +18% |
| Working capital & other | $16.5M | $9.0M | $7.6M | +84% |
| Operating cash flow | $12.5M | $9.1M | $3.4M | +37% |
Questions
How much did BillionToOne's revenue grow quarter over quarter in Q3 2026?
BillionToOne's revenue rose $13.5M (+12%) from $109M in Q2 2026 to $123M in Q3 2026.
What drove BillionToOne's revenue change in Q3 2026?
Prenatal +$10.0M (+11%); Oncology +$3.4M (+25%); Clinical trial support and other services +$101K (+7%).